Drug
Cholebine clinical trials
Also written CHOLEBINE®, MCI-196 and colestilan.
- studies test it
- 12
- open now
- 0
- in phase 3
- 10
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
12 studies that test it; most in 2007 (5)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 5 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Tanabe Pharma Corporation (9) · Mitsubishi Tanabe Pharma Corporation (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cholebine is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaCompletedPhase 3Tanabe Pharma CorporationNCT00416520Written as MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)
- Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedPhase 3Tanabe Pharma CorporationNCT00772382Written as MCI-196
- A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaCompletedPhase 3Tanabe Pharma CorporationNCT00542386Written as MCI-196
- A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaCompletedPhase 3Tanabe Pharma CorporationNCT00506441Written as MCI-196
- Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT01976572Written as colestilan
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on DialysisCompletedPhase 3Tanabe Pharma CorporationNCT00858637Written as MCI-196
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedPhase 3Tanabe Pharma CorporationNCT00542815Written as MCI-196
- Efficacy and Safety Study of MCI-196 in Patients With Type 2 DiabetesCompletedPhase 2Tanabe Pharma CorporationNCT00497198Written as MCI-196
- Dose-finding Study of MCI-196TerminatedPhase 3Mitsubishi Tanabe Pharma CorporationNCT01814904Written as colestilan-L
- Long-term Extension Study of MCI-196TerminatedPhase 3Mitsubishi Tanabe Pharma CorporationNCT01814917Written as colestilan
- Safety and Tolerability Study of MCI-196TerminatedPhase 3Tanabe Pharma CorporationNCT01818687Written as colestilan
- A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With HyperphosphatemiaTerminatedPhase 3Mitsubishi Tanabe Pharma CorporationNCT00451295Written as MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Codes
What other systems call cholebine · ClinicalTrials.gg INT003991
- MeSH (NLM) C106574cholebineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) VSI302RYSRCOLESTILAN CHLORIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C106574 | cholebine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | VSI302RYSR | COLESTILAN CHLORIDE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.